United States: FDA's Decentralized Trial Guidance: Investigator, Health Care Provider Demarcation Raises Questions - Morrison & Foerster LLP
Friday, 28 July 2023
And if a subject is interacting with the health care system outside of the trials, what is the best way of capturing that data?"
|
||||
You Might Like |
||||
